hVIVO hails growing contract values after winning £13.6mln RSV challenge trial deal

(4:50)

hVIVO hail data on phase 2a study published in New England Journal of Medicine

(4:59)

Open Orphan subsidiary hVIVO launch of STRiVE to 'find out what people are actually suffering from'

(7:42)

hVIVO £14.7m Challenge virus manufacturing contract for top 5 global pharmaceutical client

(6:4)

hVIVO contract the fruit of increasing Asian focus

(3:56)

FluCamp Clinical Trials by hVIVO

(1:7)

CEO Appointment at Open Orphan

(4:24)

Open Orphan PLC on hVIVO signing its first phase 2 field study contract

(5:55)

Open Orphan hail £5m contract for new flu jab challenge study

(3:9)

হিল্লা বউ || বাংলা ছর্ট নাটক|| বিচাৰ পর্ব || Album india

(12:21)

Open Orphan (ORPH) - Cathal Friel, Executive Chairman

(29:42)

Open Orphan (ORPH) - Cathal Friel, CEO

(30:29)

JHA from White House - 2nd Gen Vaccines - Vaxart

(1:49)

Open Orphan (ORPH) - Cathal Friel, Executive Chairman

(30:25)

Poolbeg Pharma #POLB - Exec Chairman Cathal Friel \u0026 CEO Jeremy Skillington talk to Alan Green

(8:26)

Getting Started in OpenPLC - Tagalog

(41:9)

Poolbeg Pharma: Shareholder Q\u0026A

(9:24)

Accesso Technology Group hails 'remarkable' profitability that is 'four times 2019'

(4:51)

Open Orphan subsidiary hVIVO wins £6.2m Influenza human challenge study contract with US customer

(3:40)

The World's First Covid-19 Human Challenge Trial: The Regulatory Challenges - TOPRA Presentation

(57:1econd)

Open Orphan's Cathal Friel on the 'large opportunity' for hVIVO subsidiary malaria study

(3:1econd)

hVIVO secure MHRA approval to start Codagenix COVID-19 Phase I Vaccine Trial - BRR Media

(1:19)

CEO Yamin 'Mo' Khan on £5m RSV Challenge Study Contract

(3:45)

Open Orphan's hVIVO subsidiary begin study for human malaria infection challenge study

(4:42)

Chief Scientific Officer on Influenza Challenge Study contract Win

(5:20)

Year in Review 2021 - Open Orphan

(2:1econd)

Open Orphan: A London-listed leader clinical challenge studies

(5:8)

Open Orphan's Cathal Friel hails £4mln contract with top-three global pharma firm

(5:41)